Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Only 2 participants were enrolled
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Minority Health and Health Disparities (NIMHD) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The polycystic ovary syndrome (PCOS) affects about 10% of reproductive-age women. Women with PCOS are at a higher risk of gestational diabetes, which may lead to more pregnancy complications. It is unknown if there are factors that may predict which women are more at risk.
The goal of this study is to evaluate the risk factors of gestational diabetes, such as dietary and physical activity factors, race, and how the body handles its own hormones during pregnancy. Our long term goal is to contribute in finding ways to successfully prevent gestational diabetes.
The polycystic ovary syndrome is the leading cause of female infertility in the United States. The disorder affects approximately 6-10% of women of reproductive age. Insulin is a hormone that helps the body to take up sugar from the bloodstream. It is widely accepted that "insulin resistance" may be responsible for the polycystic ovary syndrome. Women are insulin resistant when their bodies do not respond to insulin's action to handle sugar as they normally should. Because of this insulin resistance, when women with the polycystic ovary syndrome become pregnant, they are at a higher risk of developing gestational diabetes. Gestational diabetes carries risk to both the mother and the baby. The purpose of this study is to determine whether certain factors in women with the polycystic ovary syndrome are linked to risk of gestational diabetes. We propose to look at demographic factors, as well as the body's handling of estrogen (a female hormone present in high quantities during pregnancy) in this study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| African-American women | Observational study--no intervention | ||
| Caucasian women | Observational study--no intervention |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change from Gestation Week 12-14 in Estrogen Metabolites at Gestation Week 32-34 | Gestation weeks 12-14, 24-26, and 32-34 | |
| Change from Gestation Week 12-14 in Insulin Sensitivity at Gestation Week 32-34 | Gestation weeks 12-14, 24-26, and 32-34 |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Gestation Week 12-14 in Fasting Insulin at Gestation Week 32-34 | Gestation weeks 12-14, 24-26, and 32-34 | |
| Change from Gestation Week 12-14 in Fasting Glucose at Gestation Week 32-34 | Gestation weeks 12-14, 24-26, and 32-34 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Participants will be recruited from clinics in/near Richmond, VA.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kai Cheang, Pharm. D. | Virginia Commonwealth University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Virginia Commonwealth University Medical Center | Richmond | Virginia | 23298-5051 | United States |
Not provided
| ID | Term |
|---|---|
| D011085 | Polycystic Ovary Syndrome |
| D007333 | Insulin Resistance |
| D009765 | Obesity |
| D016640 | Diabetes, Gestational |
| D018149 | Glucose Intolerance |
| D017588 | Hyperandrogenism |
| ID | Term |
|---|---|
| D010048 | Ovarian Cysts |
| D003560 | Cysts |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Change from Gestation Week 12-14 in Areas-under-the-response-curve of Insulin at Gestation Week 32-34 | Gestation weeks 12-14, 24-26, and 32-34 |
| Change from Gestation Week 12-14 in Areas-under-the-response-curve of Glucose at Gestation Week 32-34 | Gestation weeks 12-14, 24-26, and 32-34 |
| Change from Gestation 12-14 in Matsuda Insulin Sensitivity Index at Gestation Week 32-34 | Gestation weeks 12-14, 24-26, and 32-34 |
| Change from Gestation Week 12-14 in Insulin Secretory Response at Gestation Week 32-34 | Gestation weeks 12-14, 24-26, and 32-34 |
| Change from Gestation Week 12-14 in Macronutrients at Gestation Week 32-34 | Gestation weeks 12-14, 24-26, and 32-34 |
| Change from Gestation Week 12-14 in Urinary Estrogen Metabolites at Gestation Week 32-34 | Gestation weeks 12-14, 24-26, and 32-34 |
| Change from Gestation Week 12-14 in Body Weight at Gestation Week 32-34 | Gestation weeks 12-14, 24-26, and 32-34 |
| Change from Gestation Week 12-14 in Physical Activity at Gestation Week 32-34 | Gestational week 12-14, 24-26, 32-34 |
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011248 | Pregnancy Complications |
| D003920 | Diabetes Mellitus |
| D006943 | Hyperglycemia |
| D058489 | 46, XX Disorders of Sex Development |
| D012734 | Disorders of Sex Development |
| D014564 | Urogenital Abnormalities |
| D047808 | Adrenogenital Syndrome |
| D052801 | Male Urogenital Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |